PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of
a new generation of targeted treatments for cancer and immunologic diseases.
The company receives royalties for products licensed under its patents.
Company Presentations & Events
News Releases
03/03/10
PDL BioPharma to Present at the Cowen and Company 30th Annual Health Care Conference on March 9, 2010
03/02/10
PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
